The general party branch of the pharmaceutical company attended the party class.
Release time:
2020-08-14
12# July
, Yuan Jie, secretary of the general party branch of Jinhua pharmaceutical company, gave a special party class entitled "be brave, be good, and strive for a new era" for all party members, activists and league members before retirement. How do party members and cadres act in the new era? Secretary Yuan Jie elaborated on three aspects: firm ideals and beliefs, ability and quality to act, and practical actions. He said that in the new era, party members and cadres must strengthen their convictions, not forget their original aspirations, insist on arming their minds with Xi Jinping's new era of socialism with Chinese characteristics, strengthen the "four consciousnesses", and strengthen the "four confidences" with a strong sense of professionalism. Sense of responsibility, overcome difficulties and resolve social problems, and promote the great cause of reform without fear of difficulties and dangers; in the process of "practice-understanding-practice-re-re, we should constantly sum up historical experience and our own experience, improve our quality and ability to take responsibility, firmly grasp the initiative in work, solve problems and do good things with ease; we should highlight the role of leading cadres as a" key minority ", educate and guide Party members and cadres at all levels to set an example, and consciously achieve the" three leaders ": take the lead in performing their duties, take the lead in taking responsibility, Take the lead in taking responsibility, as a promotion. Be responsible, do not delay work for any reason, do not use any excuse for the absence of service, and bravely assume the responsibility. Secretary Yuan Jie also encouraged everyone with Lin Zexu's famous saying that "all rivers are open to the sea, tolerance is big, standing on the wall, and no desire is strong". He said that a person should have a broad mind like the sea, accommodate different people and different opinions, be selfless and fair in doing things, put the collective cause first, regardless of personal gains and losses. Only in this way can we achieve great things together with everyone. He hopes that all cadres and employees of the pharmaceutical company will work together, not forget their original aspirations, and strive to write a new chapter in the development and growth of the pharmaceutical company. Jin Huazhong, secretary of the party Committee of
Pharmaceutical Company, attended the party class. He said that the general party branch of the pharmaceutical company and its three subordinate party branches have organized party members to carry out rich activities in the coming
years. The "three meetings and one lesson" system has also been implemented vividly, especially in this party class, with accurate topic selection and rich content. Taking responsibility is the core quality of a communist party member. secretary yuan Jie explained from various aspects what is taking responsibility and how to take responsibility in the new era. he is clear, profound and inspired. All party members must correctly understand their responsibilities, take every responsibility of their positions, and be worthy of our responsibilities. Only in this way can they be worthy of the company's positions and the requirements of this era. At the meeting of
, Wu Weisheng, member of the general party branch and general manager of the pharmaceutical company, stressed that participating in party lessons and strengthening party spirit education are the fine traditions and effective forms of our party. He asked everyone to take an active part in party lessons to increase their knowledge of the party and enhance their understanding of party spirit. On the other hand, in the current complex and difficult situation, party members and cadres are even more required to have the spirit of responsibility, put an end to undesirable phenomena such as one hiding, two pushing and three procrastination, dare to stand up at critical moments, and dare to face difficulties. The new era needs new responsibilities, and the new era needs new actions. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page